Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus Podar

Showing results (1-10 of 150) with videos related to

Pageof 15
Sort By:
Expert Opinion on Pharmacotherapy|September 5, 2018
Choosing an appropriate salvage therapy for a patient with multiple myelomaKlaus Podar
Current Cancer Drug Targets|November 10, 2017
Editorial: Multiple Myeloma ImmunotherapiesKlaus Podar
Current Cancer Drug Targets|June 8, 2012
Novel targets and derived small molecule inhibitors in multiple myelomaKlaus Podar
Blood|June 27, 2015
Toward optimizing pomalidomide therapy in MM patientsKlaus Podar
Blood|June 22, 2023
Targeting mtDAMPed macrophages for MM therapyKlaus Podar
Blood|September 29, 2012
MM-associated anemia: more than "crowding out" HSPCsKlaus Podar
Cancers|October 23, 2021
Relapsed/Refractory Multiple Myeloma in 2020/2021 and BeyondKlaus Podar, Xavier Leleu
Cancers|June 2, 2021
The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma PathophysiologyFengjuan Fan, Klaus Podar
Expert Opinion on Biological Therapy|June 18, 2013
New insights, recent advances, and current challenges in the biological treatment of multiple myelomaSonia Vallet, Klaus Podar
Expert Opinion on Drug Discovery|February 19, 2024
The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myelomaIrene Strassl, Klaus Podar
Pageof 15

Showing results (1-10 of 150) with videos related to

Sort By:
Pageof 15
Expert Opinion on Pharmacotherapy|September 5, 2018
Choosing an appropriate salvage therapy for a patient with multiple myelomaKlaus Podar
Current Cancer Drug Targets|November 10, 2017
Editorial: Multiple Myeloma ImmunotherapiesKlaus Podar
Current Cancer Drug Targets|June 8, 2012
Novel targets and derived small molecule inhibitors in multiple myelomaKlaus Podar
Blood|June 27, 2015
Toward optimizing pomalidomide therapy in MM patientsKlaus Podar
Blood|June 22, 2023
Targeting mtDAMPed macrophages for MM therapyKlaus Podar
Blood|September 29, 2012
MM-associated anemia: more than "crowding out" HSPCsKlaus Podar
Cancers|October 23, 2021
Relapsed/Refractory Multiple Myeloma in 2020/2021 and BeyondKlaus Podar, Xavier Leleu
Cancers|June 2, 2021
The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma PathophysiologyFengjuan Fan, Klaus Podar
Expert Opinion on Biological Therapy|June 18, 2013
New insights, recent advances, and current challenges in the biological treatment of multiple myelomaSonia Vallet, Klaus Podar
Expert Opinion on Drug Discovery|February 19, 2024
The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myelomaIrene Strassl, Klaus Podar
Pageof 15